CytoDyn Inc. SEC filings CYDY

CytoDyn Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jul 15, 2015. Its latest annual report, Form 10-K, was filed on Aug 31, 2026 for the period ended May 31, 2026. The latest quarterly report (Form 10-Q) was filed on Oct 14, 2026, covering the quarter ended Aug 31, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on May 31.

CytoDyn Inc. SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Oct 19, 2026 —
8-K Current report
Officer or director change, Regulation FD disclosure
Oct 19, 2026 Oct 16, 2026
10-Q Quarterly report Oct 14, 2026 Aug 31, 2026
EFFECT Filing Oct 7, 2026 —
424B3 Prospectus Oct 7, 2026 —
EFFECT Filing Oct 2, 2026 —
EFFECT Filing Oct 2, 2026 —
DEF 14A Proxy statement Sep 28, 2026 Sep 28, 2026
S-3 Shelf registration Sep 25, 2026 —
POS AM Filing Sep 25, 2026 —
POS AM Filing Sep 25, 2026 —
10-K Annual report Aug 31, 2026 May 31, 2026
EFFECT Filing May 20, 2026 —
424B3 Prospectus May 20, 2026 —
D Filing May 11, 2026 —
8-K Current report
Regulation FD disclosure
Apr 30, 2026 Apr 30, 2026
S-1 Registration statement Apr 22, 2026 —
424B3 Prospectus Apr 8, 2026 —
10-Q Quarterly report Apr 8, 2026 Feb 28, 2026
424B3 Prospectus Mar 25, 2026 —
8-K Current report
Material agreement
Mar 24, 2026 Mar 24, 2026
424B3 Prospectus Mar 9, 2026 —
8-K Current report
Unregistered share sale
Mar 5, 2026 Feb 27, 2026
424B3 Prospectus Jan 9, 2026 —
10-Q Quarterly report Jan 9, 2026 Nov 30, 2025
424B3 Prospectus Dec 22, 2025 —
EFFECT Filing Dec 16, 2025 —
POS AM Filing Dec 10, 2025 —
EFFECT Filing Dec 2, 2025 —
424B3 Prospectus Dec 2, 2025 —
8-K Current report
Other events
Dec 1, 2025 Nov 23, 2025
CORRESP Letter to the SEC Nov 26, 2025 —
8-K Current report
Bylaw or fiscal year change, Shareholder vote results
Nov 21, 2025 Nov 21, 2025
S-3 Shelf registration Nov 4, 2025 —
DEFA14A Additional proxy material Nov 3, 2025 —
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Nov 3, 2025 Nov 3, 2025
10-Q Quarterly report Oct 10, 2025 Aug 31, 2025
DEFA14A Additional proxy material Sep 30, 2025 —
424B3 Prospectus Sep 29, 2025 —
DEF 14A Proxy statement Sep 29, 2025 Nov 21, 2025
PRE 14A Preliminary proxy statement Sep 19, 2025 Nov 21, 2025
EFFECT Filing Aug 21, 2025 —
CORRESP Letter to the SEC Aug 19, 2025 —
CORRESP Letter to the SEC Aug 18, 2025 —
UPLOAD Letter from the SEC Jul 31, 2025 —
S-3 Shelf registration Jul 25, 2025 —
10-K Annual report Jul 25, 2025 May 31, 2025
424B3 Prospectus May 16, 2025 —
8-K Current report
Auditor change
May 16, 2025 May 14, 2025
424B3 Prospectus May 6, 2025 —
8-K Current report
Officer or director change, Regulation FD disclosure
May 6, 2025 May 2, 2025
424B3 Prospectus Apr 15, 2025 —
10-Q Quarterly report Apr 14, 2025 Feb 28, 2025
424B3 Prospectus Jan 14, 2025 —
10-Q Quarterly report Jan 14, 2025 Nov 30, 2024
8-K Current report
Shareholder vote results
Nov 22, 2024 Nov 22, 2024
424B3 Prospectus Oct 17, 2024 —
10-Q Quarterly report Oct 15, 2024 Aug 31, 2024
DEF 14A Proxy statement Oct 11, 2024 Nov 22, 2024
EFFECT Filing Oct 1, 2024 —
424B3 Prospectus Oct 1, 2024 —
10-K/A Amended annual report Sep 30, 2024 May 31, 2024
CORRESP Letter to the SEC Sep 26, 2024 —
UPLOAD Letter from the SEC Sep 17, 2024 —
EFFECT Filing Sep 12, 2024 —
EFFECT Filing Sep 12, 2024 —
POS AM Filing Sep 9, 2024 —
POS AM Filing Sep 9, 2024 —
S-1 Registration statement Sep 9, 2024 —
10-K Annual report Aug 15, 2024 May 31, 2024
SC TO-I/A Filing Jul 22, 2024 —
424B3 Prospectus Jul 9, 2024 —
424B3 Prospectus Jul 9, 2024 —
SC TO-I/A Filing Jul 9, 2024 —
8-K Current report
Regulation FD disclosure, Other events
Jul 9, 2024 Jul 2, 2024
CORRESP Letter to the SEC Jun 28, 2024 —
SC TO-I/A Filing Jun 28, 2024 —
8-K Current report
Auditor change
Jun 28, 2024 Jun 28, 2024
CORRESP Letter to the SEC Jun 20, 2024 —
SC TO-I/A Filing Jun 20, 2024 —
CORRESP Letter to the SEC Jun 12, 2024 —
UPLOAD Letter from the SEC Jun 10, 2024 —
8-K Current report
Unregistered share sale
Jun 3, 2024 May 28, 2024
SC TO-I Filing Jun 3, 2024 —
424B3 Prospectus May 6, 2024 —
424B3 Prospectus May 6, 2024 —
8-K Current report
Auditor change
May 6, 2024 May 6, 2024
424B3 Prospectus Apr 16, 2024 —
424B3 Prospectus Apr 16, 2024 —
10-Q Quarterly report Apr 15, 2024 Feb 29, 2024
424B3 Prospectus Apr 8, 2024 —
424B3 Prospectus Apr 8, 2024 —
8-K Current report
Agreement ended
Apr 8, 2024 Apr 3, 2024
8-K Current report
Unregistered share sale
Mar 28, 2024 Mar 22, 2024
424B3 Prospectus Mar 1, 2024 —
424B3 Prospectus Mar 1, 2024 —
424B3 Prospectus Feb 22, 2024 —
EFFECT Filing Feb 21, 2024 —
CORRESP Letter to the SEC Feb 15, 2024 —
UPLOAD Letter from the SEC Feb 13, 2024 —
S-1 Registration statement Feb 7, 2024 —
424B3 Prospectus Jan 29, 2024 —
8-K Current report
Officer or director change, Regulation FD disclosure
Jan 29, 2024 Jan 23, 2024
424B3 Prospectus Jan 19, 2024 —
10-Q Quarterly report Jan 16, 2024 Nov 30, 2023
8-K Current report
Other events
Dec 22, 2023 Dec 19, 2023
424B3 Prospectus Dec 15, 2023 —
8-K Current report
Other events
Dec 14, 2023 Dec 14, 2023
424B3 Prospectus Nov 28, 2023 —
8-K Current report
Agreement ended
Nov 28, 2023 Nov 21, 2023
424B3 Prospectus Nov 22, 2023 —
8-K Current report
Officer or director change, Regulation FD disclosure
Nov 21, 2023 Nov 17, 2023
424B3 Prospectus Nov 13, 2023 —
8-K Current report
Bylaw or fiscal year change, Shareholder vote results
Nov 9, 2023 Nov 9, 2023
8-K Current report
Regulation FD disclosure
Nov 6, 2023 Nov 3, 2023
DEFA14A Additional proxy material Nov 6, 2023 —
424B3 Prospectus Oct 24, 2023 —
10-Q Quarterly report Oct 23, 2023 Aug 31, 2023
NT 10-Q Filing Oct 16, 2023 Aug 31, 2023
424B3 Prospectus Oct 11, 2023 —
DEFA14A Additional proxy material Oct 10, 2023 —
8-K Current report
Auditor change
Oct 10, 2023 Oct 6, 2023
EFFECT Filing Oct 5, 2023 —
POS AM Filing Oct 2, 2023 —
DEFA14A Additional proxy material Sep 27, 2023 —
DEF 14A Proxy statement Sep 25, 2023 Nov 9, 2023
8-K Current report
Auditor change
Sep 25, 2023 Sep 19, 2023
PRE 14A Preliminary proxy statement Sep 15, 2023 Nov 9, 2023
10-K Annual report Sep 14, 2023 May 31, 2023
NT 10-K Filing Aug 30, 2023 May 31, 2023
8-K Current report
Unregistered share sale
Aug 17, 2023 Aug 11, 2023
424B3 Prospectus Jul 11, 2023 —
8-K Current report
Officer or director change, Regulation FD disclosure
Jul 11, 2023 Jul 6, 2023
EFFECT Filing Jul 10, 2023 —
CORRESP Letter to the SEC Jul 6, 2023 —
UPLOAD Letter from the SEC Jun 26, 2023 —
S-1 Registration statement Jun 21, 2023 —
8-K Current report
Officer or director change, Regulation FD disclosure
May 24, 2023 May 18, 2023
10-Q Quarterly report Apr 10, 2023 Feb 28, 2023
8-K Current report
Unregistered share sale
Mar 8, 2023 Mar 2, 2023
8-K Current report
Unregistered share sale
Mar 2, 2023 Feb 24, 2023
EFFECT Filing Feb 9, 2023 —
EFFECT Filing Feb 9, 2023 —
EFFECT Filing Feb 9, 2023 —
EFFECT Filing Feb 9, 2023 —
EFFECT Filing Feb 9, 2023 —
EFFECT Filing Feb 9, 2023 —
EFFECT Filing Feb 9, 2023 —
EFFECT Filing Feb 9, 2023 —
POS AM Filing Feb 3, 2023 —
POS AM Filing Feb 3, 2023 —
POS AM Filing Feb 3, 2023 —
POS AM Filing Feb 3, 2023 —
POS AM Filing Feb 3, 2023 —
POS AM Filing Feb 3, 2023 —
POS AM Filing Feb 3, 2023 —
POS AM Filing Feb 3, 2023 —
8-K Current report
Unregistered share sale
Feb 1, 2023 Jan 26, 2023
10-Q Quarterly report Jan 9, 2023 Nov 30, 2022
8-K Current report
Officer or director change
Dec 19, 2022 Dec 19, 2022
8-K Current report
Shareholder vote results
Dec 9, 2022 Dec 9, 2022
DEFA14A Additional proxy material Dec 7, 2022 —
8-K Current report
Regulation FD disclosure
Dec 7, 2022 Dec 7, 2022
DEFA14A Additional proxy material Dec 7, 2022 —
8-K Current report
Material agreement, Unregistered share sale
Dec 7, 2022 Nov 30, 2022
DEFA14A Additional proxy material Nov 25, 2022 —
8-K Current report
Officer or director change
Nov 25, 2022 Nov 21, 2022
8-K Current report
Regulation FD disclosure, Other events
Oct 28, 2022 Oct 28, 2022
DEF 14A Proxy statement Oct 26, 2022 Dec 9, 2022
8-K Current report
Officer or director change
Oct 19, 2022 Oct 13, 2022
10-Q/A Amended quarterly report Oct 13, 2022 Aug 31, 2022
10-Q Quarterly report Oct 11, 2022 Aug 31, 2022
EFFECT Filing Sep 30, 2022 —
CORRESP Letter to the SEC Sep 28, 2022 —
10-K/A Amended annual report Sep 28, 2022 May 31, 2022
RW Filing Sep 26, 2022 —
UPLOAD Letter from the SEC Sep 21, 2022 —
D/A Filing Sep 19, 2022 —
S-3 Shelf registration Sep 14, 2022 —
EFFECT Filing Sep 2, 2022 —
424B3 Prospectus Sep 2, 2022 —
8-K Current report
Bylaw or fiscal year change, Shareholder vote results
Aug 31, 2022 Aug 31, 2022
8-K Current report
Officer or director change
Aug 30, 2022 Aug 24, 2022
CORRESP Letter to the SEC Aug 30, 2022 —
UPLOAD Letter from the SEC Aug 29, 2022 —
S-3 Shelf registration Aug 23, 2022 —
10-K Annual report Aug 15, 2022 May 31, 2022
8-K Current report
Restatement
Aug 5, 2022 Aug 4, 2022
NT 10-K Filing Aug 1, 2022 May 31, 2022
8-K/A Amended current report
Unregistered share sale
Jul 25, 2022 Jun 24, 2022
8-K Current report
Material agreement
Jul 25, 2022 Jul 18, 2022
DEF 14A Proxy statement Jul 22, 2022 Aug 31, 2022
PRE 14A Preliminary proxy statement Jul 8, 2022 Aug 31, 2022
8-K Current report
Unregistered share sale, Officer or director change
Jun 30, 2022 Jun 24, 2022
8-K Current report
Unregistered share sale
May 31, 2022 May 24, 2022
8-K Current report
Material agreement, Unregistered share sale, Officer or director change
May 23, 2022 May 17, 2022
8-K Current report
Unregistered share sale
May 12, 2022 May 6, 2022
8-K Current report
Unregistered share sale
May 5, 2022 Apr 29, 2022
8-K Current report
Officer or director change
Apr 25, 2022 Apr 19, 2022
D/A Filing Apr 25, 2022 —

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CYDY (OTC)
Fiscal year ends
May 31
Incorporated in
DE
Headquarters
Vancouver, WA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1175680
Former names
CYTODYN INC (until Apr 13, 2016); REXRAY CORP (until Nov 12, 2003)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.